Mission Therapeutics
PITCH
Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
LATEST INVESTMENT
£25.2M
Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, & Rosetta Capital
Mission Therapeutics
£12M
Pfizer Ventures, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, Schroders Adveq